ANAB
Price
$55.20
Change
+$0.14 (+0.25%)
Updated
Sep 18 closing price
Capitalization
1.63B
51 days until earnings call
Intraday BUY SELL Signals
CLRB
Price
$2.38
Change
-$0.02 (-0.83%)
Updated
Sep 18 closing price
Capitalization
22.5M
39 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANAB vs CLRB

ANAB vs CLRB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANAB vs. CLRB commentary
Sep 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a Hold and CLRB is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANAB($1.63B) has a higher market cap than CLRB($22.5M). ANAB has higher P/E ratio than CLRB: ANAB (97.09) vs CLRB (20.22). ANAB YTD gains are higher at: 70.817 vs. CLRB (-19.322). ANAB has higher annual earnings (EBITDA): 58.5M vs. CLRB (-23.5M). ANAB has more cash in the bank: 286M vs. CLRB (34M). CLRB has less debt than ANAB: CLRB (1.53M) vs ANAB (13.6M). ANAB has higher revenues than CLRB: ANAB (232M) vs CLRB (0).
ANABCLRBANAB / CLRB
Capitalization1.63B22.5M7,262%
EBITDA58.5M-23.5M-249%
Gain YTD70.817-19.322-367%
P/E Ratio97.0920.22480%
Revenue232M0-
Total Cash286M34M841%
Total Debt13.6M1.53M888%
FUNDAMENTALS RATINGS
ANAB vs CLRB: Fundamental Ratings
ANAB
CLRB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
21100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3680
P/E GROWTH RATING
1..100
6463
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLRB's Valuation (75) in the Biotechnology industry is in the same range as ANAB (95). This means that CLRB’s stock grew similarly to ANAB’s over the last 12 months.

ANAB's Profit vs Risk Rating (21) in the Biotechnology industry is significantly better than the same rating for CLRB (100). This means that ANAB’s stock grew significantly faster than CLRB’s over the last 12 months.

ANAB's SMR Rating (99) in the Biotechnology industry is in the same range as CLRB (99). This means that ANAB’s stock grew similarly to CLRB’s over the last 12 months.

ANAB's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for CLRB (80). This means that ANAB’s stock grew somewhat faster than CLRB’s over the last 12 months.

CLRB's P/E Growth Rating (63) in the Biotechnology industry is in the same range as ANAB (64). This means that CLRB’s stock grew similarly to ANAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANABCLRB
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
89%
Momentum
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 10 days ago
80%
Bearish Trend 18 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
87%
Aroon
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
88%
COMPARISON
Comparison
Sep 21, 2026
Stock price -- (ANAB: $55.20 vs. CLRB: $2.38)
Brand notoriety: ANAB and CLRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANAB: 210% vs. CLRB: 188%
Market capitalization -- ANAB: $1.63B vs. CLRB: $22.5M
ANAB [@Biotechnology] is valued at $1.63B. CLRB’s [@Biotechnology] market capitalization is $22.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $128.84B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANAB’s FA Score shows that 1 FA rating(s) are green while CLRB’s FA Score has 0 green FA rating(s).

  • ANAB’s FA Score: 1 green, 4 red.
  • CLRB’s FA Score: 0 green, 5 red.
According to our system of comparison, ANAB is a better buy in the long-term than CLRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANAB’s TA Score shows that 3 TA indicator(s) are bullish while CLRB’s TA Score has 5 bullish TA indicator(s).

  • ANAB’s TA Score: 3 bullish, 5 bearish.
  • CLRB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CLRB is a better buy in the short-term than ANAB.

Price Growth

ANAB (@Biotechnology) experienced а +2.47% price change this week, while CLRB (@Biotechnology) price change was +3.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.53%. For the same industry, the average monthly price growth was -8.46%, and the average quarterly price growth was +7.13%.

Reported Earning Dates

ANAB is expected to report earnings on Nov 10, 2026.

CLRB is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (+1.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ANAB
Daily Signal:
Gain/Loss:
CLRB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VSOL15.371.81
+13.39%
VanEck Solana ETF (VSOL)
FETH26.281.90
+7.79%
Fidelity Ethereum Fund ETF (FETH)
KBWY17.15-0.21
-1.21%
Invesco KBW Premium Yield Equity REIT ETF (KBWY)
IBBQ34.69-0.44
-1.24%
Invesco Nasdaq Biotechnology ETF (IBBQ)
CPNX10.15-0.30
-2.89%
Tradr 2X Long CPNG Daily ETF (CPNX)